Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030784 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL2033607 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL9402156 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL28129969 | 0.82 | CYP1A2 (0.47) | SMN1; SMN2HIF1ACYP1A2CTSC | |
| Methionine SCHEMBL4636642 | 0.80 | KIF11 (0.45) | SMN1; SMN2HIF1A | |
| SCHEMBL1081531 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL9554357 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL2129592 | 0.77 | HIF1A (0.50) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL27531147 | 0.76 | ALDH1A1 (0.46) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1750351 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516130-B2 | Single-domain antibody for targeting prostate specific membrane antigen (PSMA) | NATIONAL INSTITUTE OF BIOTECHNOLOGY IN THE NEGEV LTD. (IL) | 2026-01-06 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| CN-108368161-A | Peptidomimetic macrocycles as MC L-1 modulators | 艾瑞朗医疗公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-108348571-A | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | 艾瑞朗医疗公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-107614003-A | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | 艾瑞朗医疗公司 | 2018-01-19 | — | — | CN | disclosed |
| CN-107216380-A | Peptidomimetic macrocyclic compound | 爱勒让治疗公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-107106642-A | Peptidomimetic macrocycles and formulations thereof | 艾瑞朗医疗公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-106999541-A | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | 艾瑞朗医疗公司 | 2017-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | SMN1; SMN2 3692/4885HIF1A 1850/4885SLC6A2 3765/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | SMN1; SMN2 3692/4885HIF1A 1850/4885SLC6A2 3765/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SMN1; SMN2 3692/4885HIF1A 1850/4885SLC6A2 3765/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SMN1; SMN2 3692/4885HIF1A 1850/4885SLC6A2 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.